NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this Phase I study is to determine the recommended phase 2 dose (RP2D) and safety profile of NBTXR3 activated by radiation therapy with concurrent chemotherapy for the treatment of patients with esophageal adenocarcinoma. NBTXR3 is a drug that when activated by radiation therapy, may cause targeted destruction of cancer cells. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as oxaliplatin, fluorouracil, capecitabine, docetaxel, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving NBTXR3 activated by radiation therapy with concurrent chemotherapy may help control the disease.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony biopsją rak gruczołowy przełyku (szyjnego, piersiowego lub połączenia przełyku ze żołądkiem)
- •Zaawansowana faza choroby (stadium II lub III)
- •Możliwość otrzymania chemioterapii i radioterapii jednocześnie
- •Możliwość wstrzyknięcia leku NBTXR3 za pomocą endoskopu ultradźwiękowego
- •Dostępne zmianę nowotworowe mierzalne na obrazach radiologicznych
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu
- •Wystarczające wartości składników krwi: hemoglobina, płytki krwi, białe krwinki
- •Prawidłowa funkcja nerek i wątroby
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
M D Anderson Cancer Center
Houston, United States
Trial contact
Steven H. Lin
Steven H. Lin
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.